Navigation Links
E6 Ventures Invests in Novel Coatings Developer, Diamond Hard Surfaces Ltd
Date:11/24/2008

ions and differing component finished conditions with coating thickness that ranges from one to 60 microns.

The low temperatures at which the coating can be applied mean that there is minimal effect on the substrate material and the process is applicable to a wide range of materials. Unlike other coatings, Adamant(TM) diamond hard surfaces do not require sophisticated and lengthy sub-layer preparation for many substrates.

The Oxford-based company recently won its first production orders for mechanical seals used in compressors and pumps in the oil/gas industry. Test coatings are being carried out with potential customers for a range of applications from ball/gate valves to down-hole oil drilling to Formula One engine components.

About E6 Ventures

E6 Ventures is a US$100m fund open to a broad range of investment opportunities across industry, provided they meet its investment criteria. The aim is to be recognised as an active investor in new applications, new markets, new technologies and new companies with investments that range from seed / early stage start-ups, to growth and late stage investments with the primary aim of bringing a strong return on investment.

About Element Six

Element Six is the world's leading supplier of supermaterials used throughout manufacturing industry for a wide range of applications. It is the frontrunner in the development of synthetic diamond and novel engineering materials that are being used in industrial applications that span, for example optical, mechanical, thermal, electronic, automotive, telecommunications and medical industries. With a turnover approaching US$500m and almost 4,000 employees, Element Six has established production and processing plants in China, Germany, Ireland, Sweden, South Africa, Ukraine and the UK supported by a global distribution network.

    For more information contact:
    Brendon 
'/>"/>
SOURCE Element Six Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Radius Ventures Announces Promotion of Dr. David Stoffel to Partner
2. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
3. Element Six Signals Ambitions for Growth With Senior Appointment for New Ventures Unit
4. Triage Wireless Raises $20.3 Million in Series B Financing Round Led by Qualcomm Ventures
5. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
6. Astute Medical Raises $6.2 Million in Series A Financing Round Led by De Novo Ventures
7. Oikos Organic Greek Yogurt Ventures into the Land of Milk and Honey ... and Blueberry!
8. Step of Mind Ltd Will Present its Concept at the Silicom Ventures Summit
9. Eagle Ventures Subsidiary Hydrate2O Receives 2008 Top Gear of the Year Award From ShapeYou.com
10. Khosla Ventures Into Healthcare With ZocDoc
11. Trident Capital and Mustang Ventures Lead Series A Investment in Profex, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
(Date:9/2/2014)... their own spread throughout the body by coaxing cells ... to a new report by Johns Hopkins scientists. , ... Communications , the researchers describe animal and cell-culture experiments ... by breast cancer cells. These molecules cause lymphatic endothelial ... produce proteins called CCL5 and VEGF. CCL5 attracts tumor ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Melatonin supplements did not ... fractures, a new study found. Many older hospital ... due to disruption of their normal sleep-wake cycle. A ... that contributes to delirium, but there has been little ... This study included 378 patients, average age 84, ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... screening program to detect peripheral arterial disease (PAD) on time ... For Life? this program can help detect the onset of ... of having an amputation by half. // ... affects every vascular bed in the body and it increases ...
... has the remarkable ability to discriminate between self and ... immune system, the human body would have lost its ... // ,The immune system produces certain substances ... cells, effectively labeling them as "bad" so that other ...
... Baptist Medical Center certain herbs and dietary supplements can ... other gastrointestinal problems.// ,The researcher Kemper, had ... were out there doing, and came up with a ... historically, 50 years ago, people used home remedies. Then ...
... unusual antibiotics that have the potential to be effective ... at the 230th national meeting of the American Chemical ... ,The new antibiotics are synthetic forms of cephalosporin, a ... kill bacteria by masquerading as components of the bacterial ...
... a research team led by the National Human Genome ... experimental anti-cancer drugs also shows promise in laboratory studies ... aging. // ,These drugs belong to a ... tested in people with myeloid leukemia, neurofibromatosis and other ...
... loss of interest in eating during old age is the ... a plan which will help older people eat nutritious food ... ,Doctors at the institute advise that High fibre in ... can help fight diabetes, heart disease and diverticulosis. Folic acid ...
Cached Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2Health News:Atypical Antibiotics For Super Bugs 2
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: